Literature DB >> 33658037

mRNA in cancer immunotherapy: beyond a source of antigen.

Karine Breckpot1, Sandra Van Lint2,3, Lien Van Hoecke4,5, Rein Verbeke6,7, Heleen Dewitte6,7, Ine Lentacker6,7, Karim Vermaelen7,8.   

Abstract

mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature's core building blocks carrying important information and can be considered as a powerful vector for delivery of therapeutic proteins to the patient.For a long time, the major focus in the use of in vitro transcribed mRNA was on development of cancer vaccines, using mRNA encoding tumor antigens to modify dendritic cells ex vivo. However, the versatility of mRNA and its many advantages have paved the path beyond this application. In addition, due to smart design of both the structural properties of the mRNA molecule as well as pharmaceutical formulations that improve its in vivo stability and selective targeting, the therapeutic potential of mRNA can be considered as endless.As a consequence, many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. This review aims to summarize the state-of-the-art on these applications and to provide a rationale for their clinical application.

Entities:  

Keywords:  Antibody; Cancer; Cytokine; Dendritic cell; Nanoparticle; T cell; Tumor microenvironment; mRNA

Year:  2021        PMID: 33658037      PMCID: PMC7926200          DOI: 10.1186/s12943-021-01329-3

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  128 in total

1.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors:  Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

2.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

Authors:  Katalin Karikó; Hiromi Muramatsu; Frank A Welsh; János Ludwig; Hiroki Kato; Shizuo Akira; Drew Weissman
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

Review 3.  The ReNAissanCe of mRNA-based cancer therapy.

Authors:  Sandra Van Lint; Dries Renmans; Katrijn Broos; Heleen Dewitte; Ine Lentacker; Carlo Heirman; Karine Breckpot; Kris Thielemans
Journal:  Expert Rev Vaccines       Date:  2014-09-29       Impact factor: 5.217

4.  RNA synthesis: strategies for the use of bacteriophage RNA polymerases.

Authors:  G Krupp
Journal:  Gene       Date:  1988-12-10       Impact factor: 3.688

5.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Authors:  Akin Akinc; William Querbes; Soma De; June Qin; Maria Frank-Kamenetsky; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Kallanthottathil G Rajeev; William L Cantley; J Robert Dorkin; James S Butler; Liuliang Qin; Timothy Racie; Andrew Sprague; Eugenio Fava; Anja Zeigerer; Michael J Hope; Marino Zerial; Dinah W Y Sah; Kevin Fitzgerald; Mark A Tracy; Muthiah Manoharan; Victor Koteliansky; Antonin de Fougerolles; Martin A Maier
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

Review 6.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

7.  Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.

Authors:  Katalin Karikó; Hiromi Muramatsu; Jason M Keller; Drew Weissman
Journal:  Mol Ther       Date:  2012-02-14       Impact factor: 11.454

8.  Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L.

Authors:  Bart R Anderson; Hiromi Muramatsu; Babal K Jha; Robert H Silverman; Drew Weissman; Katalin Karikó
Journal:  Nucleic Acids Res       Date:  2011-08-03       Impact factor: 16.971

9.  The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity.

Authors:  Damya Laoui; Jiri Keirsse; Yannick Morias; Eva Van Overmeire; Xenia Geeraerts; Yvon Elkrim; Mate Kiss; Evangelia Bolli; Qods Lahmar; Dorine Sichien; Jens Serneels; Charlotte L Scott; Louis Boon; Patrick De Baetselier; Massimiliano Mazzone; Martin Guilliams; Jo A Van Ginderachter
Journal:  Nat Commun       Date:  2016-12-23       Impact factor: 14.919

10.  Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing.

Authors:  Qiang Cheng; Tuo Wei; Lukas Farbiak; Lindsay T Johnson; Sean A Dilliard; Daniel J Siegwart
Journal:  Nat Nanotechnol       Date:  2020-04-06       Impact factor: 40.523

View more
  7 in total

Review 1.  The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma.

Authors:  Madison Ernst; Alessio Giubellino
Journal:  Biomedicines       Date:  2022-03-31

Review 2.  Systematic Investigation of Biocompatible Cationic Polymeric Nucleic Acid Carriers for Immunotherapy of Hepatocellular Carcinoma.

Authors:  Mingsheng Chen; Hao Wang; Hongying Guo; Ying Zhang; Liang Chen
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

3.  Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer.

Authors:  Manfred Welslau; Volkmar Müller; Diana Lüftner; Florian Schütz; Elmar Stickeler; Peter A Fasching; Wolfgang Janni; Christoph Thomssen; Isabell Witzel; Tanja N Fehm; Erik Belleville; Simon Bader; Katharina Seitz; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P Lux; Bahriye Aktas; Maggie Banys-Paluchowski; Andreas Schneeweiss; Nadia Harbeck; Rachel Würstlein; Andreas D Hartkopf; Achim Wöckel; Barbara Seliger; Chiara Massa; Hans-Christian Kolberg
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-06-03       Impact factor: 2.754

Review 4.  Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Authors:  Zhifeng Li; Dazhuang Yang; Ting Guo; Mei Lin
Journal:  Biomolecules       Date:  2022-07-06

Review 5.  Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy.

Authors:  Hong-Li Wang; Zhi-Gang Wang; Shu-Lin Liu
Journal:  Molecules       Date:  2022-08-31       Impact factor: 4.927

Review 6.  mRNA vaccines for COVID-19 and diverse diseases.

Authors:  Abid Hussain; Haiyin Yang; Mengjie Zhang; Qing Liu; Ghallab Alotaibi; Muhammad Irfan; Huining He; Jin Chang; Xing-Jie Liang; Yuhua Weng; Yuanyu Huang
Journal:  J Control Release       Date:  2022-03-21       Impact factor: 11.467

Review 7.  Epitranscriptomic signatures in stem cell differentiation to the neuronal lineage.

Authors:  Aida Șelaru; Marieta Costache; Sorina Dinescu
Journal:  RNA Biol       Date:  2021-09-28       Impact factor: 4.652

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.